Slide 1: 2013 First half results
2013 First half results 25 JULY 2013
Slide 2: First half 2013 highlights
First half 2013 highlights • Revenue € 477.7 million, up 13.8%. • EBITDA € 120.0 million or 25.1% of sales, up 17.4% • Operating income (EBIT) € 102.6 million or 21.5% of sales, up 13.8% • Net income € 70.3 million or 14.7% of sales, up 11.1% • Successful conclusion of the acquisition of a portfolio
Slide 3: Main product sales
Main product sales Corporate products including orphan drugs now account for 46.4% of revenue (million Euro) 1H 2013 1H 2012 Change % Zanidip® (lercanidipine) 61.3 61.6 (0.6) Zanipress® (lercanidipine+enalapril) 29.3 24.2 21.0 Urorec® (silodosin) 22.7 14.5 55.9 Livazo® (pitavastatin) 11.2 7.0 59.7 O
Slide 4: A richer product portfolio
A richer product portfolio Orphan drugs 12.7% Other corporate products 6.1% OTC 16.5% Livazo 2.3% Urorec 4.7% Zanipress 6.1% Zanidip 12.8% Subsidiaries’ local product portfolios 34.2% Pharmaceutical chemicals 3.6% Other revenue 1.0% Data: First half 2013 Total revenue € 477.7 m 4
Slide 5: Composition of revenue
Composition of revenue New markets and new products drive growth (million Euro) 1H 2013 1H 2012 Change % Italy 120.7 114.9 5.0 France 57.2 62.3 (8.3) Russia and other CIS countries 44.6 22.3 100.3 Germany 37.0 33.4 10.8 Turkey 34.8 31.8 9.5 U.S.A. 23.9 3.4 n.s. Portugal 15.7 16.9 (7.4) Spain 15.6 17
Slide 6: A growing presence in Eastern Europe, Turkey and the U.S.A.
A growing presence in Eastern Europe, Turkey and the U.S.A. Russia and other CIS 9.7% Germany 8.0% France 12.4% Turkey 7.6% USA 5.2% Portugal 3.4% Italy 26.2% Spain 3.4% Other W. Europe countries 2.7% Other CEE 3.7% Other international sales 17.7% (sales to licensees and exports) Data: First half 20
Slide 7: First half 2013 results
First half 2013 results Significant sales and earnings growth (million Euro) 1Q 2013 1Q 2012 Change % Revenue 477.7 419.9 13.8 Gross Profit 312.1 272.4 14.6 as % of revenue 65.3 64.9 SG&A Expenses 169.7 151.6 11.9 as % of revenue 35.5 36.1 R&D Expenses 37.9 28.8 31.9 as % of revenue 7.9 6.9 Other In
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Jun 2013 31 Dec 2012 Change Cash and short-term financial 42.4 38.4 4.0 investments Bank overdrafts and short-term loans (30.5) (56.0) 25.5 Loans – due within one year (8.1) (8.1) 0.0 Loans – due after one year (176.8) (127.7) (49.0) NET
Slide 9: Financial projections
Financial projections 2013 targets and plan for 2015 2012 2013 2015 (million Euro) Actual Targets Plan Revenue 828.3 ̴ 930 1,025 -1,075 Operating income 167.0 ̴ 190 210 - 220 (EBIT) Net Income 118.5 ̴132 140 - 150 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan